May 2, 2009

Histidine-tryptophan-ketoglutarate (HTK) is associated with reduced graft survival of deceased donor kidney transplants.


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

University of Wisconsin (UW) solution has been the standard solution used for cold preservation for many years, while HTK is a newer, less expensive solution which appears to have several characteristics which would reduce ischemia-reperfusion injury. However, in this study from the UNOS database, HTK solution was associated with a late increased risk of death-censored graft loss, despite the lack of an impact on delayed graft function. There are no randomized controlled trials comparing these solutions, but this study may cause centers to reevaluate their use of HTK.

Renal Transplantation